الفهرس 
Short duration for easy to treat patients generic sofosbuvir / ledipasvir treatment of Nai?ve, non-cirrhotic patients with chronic HCV infection
استخدام عقار السوفسبوفير و ليديباسفيرالمكافىء فى علاج التهاب الكبد الوبائى المزمن ج لفتره قصيره للمرضى الذين يسهل علاجهم والذين لم يتلقوا علاج مضاد للفيروس من قبل وغير مصابون بتليف كبدى لمده ثمانيه اسابيع مقابل اثنى عشر اسبوعاOnly 14 pages are availabe for public view
 |  | from | 75 |  |  |
| | | from | 75 | | |
Abstract
Sofosbuvir is the cornerstone of the current IFN-free regimens for treatment of HCV genotype 4, achieving high sustained virologic response 12 weeks post treatment (SVR12) with a good safety profile. High rates of SVR were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. Aim of work: This study aims to assess the treatment response of naïve non-cirrhotic Egyptian chronic hepatitis C patients to Generic sofosbuvir/ledipasvir combination therapy for either 8 weeks or 12 weeks of therapy patients and methods: The study was conducted on 40 naive patients with HCV genotype 4 without cirrhosis who were randomly assigned to Generic sofosbuvir/ledipasvir for 8 weeks or 12 weeks. The primary end point was sustained virologic response at 12 weeks after the end of therapy. Results: 57.5% of studied patients were females with mean age 39.4 years. There was no significant difference among the 2 groups of patients in pre-treatment demographic, laboratory features, AFP, viral load or fibrosis stage. A more significant reduction of liver enzymes was noticed in group 2. The rate of SVR12 was 100% with 8 weeks of generic sofosbuvir/ledipasvir and 95% with 12 weeks of the same regimen. Conclusion: Generic sofosbuvir/Ledipasvir for 8 weeks was associated with a high rate of SVR12 among previously untreated patients with HCV genotype 4 infection without cirrhosis. No additional benefit was associated with extension of the duration of treatment to 12 weeks